New combo approach may extend life for advanced liver cancer patients

This study looks at people with liver cancer that has spread to a few spots outside the liver. All participants first get a combination of two drugs (sintilimab and lenvatinib). Those whose cancer is controlled are then randomly assigned to either continue the drugs alone or also receive local treatments like radiation or ablation to destroy remaining tumors. The goal is to see if adding local therapy helps people live longer. About 400 adults aged 18 to 75 will take part.